These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36413451)

  • 1. Effects of COVID-19 on Patients with Inflammatory Bowel Disease.
    Kogan L; Ungaro RC; Caldera F; Shah SA
    R I Med J (2013); 2022 Dec; 105(10):42-47. PubMed ID: 36413451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Doherty J; Fennessy S; Stack R; O' Morain N; Cullen G; Ryan EJ; De Gascun C; Doherty GA
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1110-1123. PubMed ID: 34472643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
    Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
    Front Immunol; 2022; 13():920333. PubMed ID: 35865529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
    Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA
    J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.
    Macaluso FS; Principi M; Facciotti F; Contaldo A; Todeschini A; Saibeni S; Bezzio C; Castiglione F; Nardone OM; Spagnuolo R; Fantini MC; Riguccio G; Caprioli F; Viganò C; Felice C; Fiorino G; Correale C; Bodini G; Milla M; Scardino G; Vernero M; Desideri F; Mannino M; Rizzo G; Orlando A;
    Dig Liver Dis; 2023 Feb; 55(2):154-159. PubMed ID: 36127228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.
    Frey S; Chowdhury R; Connolly CM; Werbel WA; Segev DL; Parian AM;
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1609-1612.e1. PubMed ID: 34998996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.
    Sung KY; Chang TE; Wang YP; Lin CC; Chang CY; Hou MC; Lu CL
    J Chin Med Assoc; 2022 Apr; 85(4):421-430. PubMed ID: 34974509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
    Suria C; Bosca-Watts MM; Navarro P; Tosca J; Anton R; Sanahuja A; Revaliente M; Minguez M
    Gastroenterol Hepatol; 2022 May; 45(5):383-389. PubMed ID: 34171421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
    Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
    Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.
    Wellens J; Colombel JF; Satsangi JJ; Wong SY
    J Crohns Colitis; 2021 Aug; 15(8):1376-1386. PubMed ID: 33721882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease.
    Reuken PA; Andreas N; Grunert PC; Glöckner S; Kamradt T; Stallmach A
    J Crohns Colitis; 2022 Feb; 16(2):251-258. PubMed ID: 34379729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression.
    Bhurwal A; Mutneja H; Bansal V; Goel A; Arora S; Attar B; Minacapelli CD; Kochhar G; Chen LA; Brant S; Seril D
    Aliment Pharmacol Ther; 2022 May; 55(10):1244-1264. PubMed ID: 35355306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.
    Esposito S; Caminiti C; Giordano R; Argentiero A; Ramundo G; Principi N
    Front Immunol; 2022; 13():933774. PubMed ID: 35812420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
    Jena A; James D; Singh AK; Dutta U; Sebastian S; Sharma V
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1456-1479.e18. PubMed ID: 35189387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
    Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
    J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].
    Lee YJ; Kim SE; Park YE; Chang JY; Song HJ; Kim DH; Yang YJ; Kim BC; Lee JG; Yang HC; Choi M; Myung SJ;
    Korean J Gastroenterol; 2021 Aug; 78(2):117-128. PubMed ID: 34446634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.